Investigating the Agonistic Requirements of anti human 4-1BB monoclonal antibodies

近几十年来，免疫疗法已经成为一种很有前途的癌症治疗方法。其成功的一个关键因素是能够使用单克隆抗体（mab）通过阻断T细胞抑制分子来激活细胞毒性T细胞对肿瘤的反应。然而，这种方法仅对一小部分肿瘤类型有效，许多患者没有反应，因此需要新的免疫激活疗法来改善治疗结果。靶向免疫刺激受体4-1BB的单克隆抗体有望作为癌症治疗药物，然而，对其作为免疫激动剂的功效调节特性的了解尚缺乏。对于靶向与4-1BB相同家族的其他受体的单克隆抗体，某些分子特征，如表位和单克隆抗体同型，已被证明会影响其激动活性的强度。

In recent decades, immunotherapy has emerged as a promising therapeutic approach for cancer. A key factor to its success has been the ability to use monoclonal antibodies (mAbs) to activate cytotoxic T cell responses against tumours by blocking T cell inhibitory molecules. However, this approach is only effective in a fraction of tumour types and many patients do not respond, highlighting the need for novel immune-activating therapies to improve therapeutic outcomes. mAbs targeting the immunostimulatory receptor 4-1BB hold promise as therapeutics for cancer, however insight into the properties modulating their efficacy as immune agonists is lacking. For mAbs targeting other receptors of the same family as 4-1BB, certain molecular characteristics, such as epitope and mAb isotype, have been shown to influence the strength of their agonistic activity.